Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is currently trading at Rs. 888.95, up by 22.25 points or 2.57% from its previous closing of Rs. 866.70 on the BSE.

The scrip opened at Rs. 879.70 and has touched a high and low of Rs. 889.95 and Rs. 876.30 respectively. So far 793643 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1200.70 on 07-Apr-2015 and a 52 week low of Rs. 748.15 on 26-Sep-2014.

Last one week high and low of the scrip stood at Rs. 889.95 and Rs. 824.70 respectively. The current market cap of the company is Rs. 213769.05 crore.

The promoters holding in the company stood at 54.71% while Institutions and Non-Institutions held 31.51% and 13.78% respectively.

Sun Pharmaceutical Industries’ one of subsidiary has entered into an agreement and plan of merger with InSite Vision Inc. (InSite Vision). InSite Vision focuses on developing new specialty ophthalmic products, including three late stage programs.

Sun Pharma is in the process of establishing a branded ophthalmic business in the US. This proposed acquisition of InSite Vision, coupled with the recent in-licensing of Xelpros (Latanoprost BAK-free eye drops) in June 2015, are steps in this direction. These deals give Sun Pharma access to four late stage branded ophthalmic products in the US.

Sun Pharma is the fifth largest specialty generic pharmaceutical company in the world. The company provides high quality, affordable medicines trusted by healthcare professionals and patients in over 150 countries worldwide.